Immunotherapy and cancer vaccine studies in various cancer types Cancer
Conditions
Interventions
Eligible patients with a number of different cancers will be approached around the time of diagnostic biopsy or surgical resection. This could be either during their initial diagnosis of cancer or at
Sponsors
NHS England
Eligibility
Sex/Gender
All
Age
16 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. Be over the age of 16 years 2. Have a tumour which has been, or will be resected or biopsied 3. Have the capacity to consent to involvement in the CVLP 4. Have sufficient tumour available for genomic analyses
Exclusion criteria
Exclusion criteria: 1. Under the age of 16 years 2. Incapable of giving informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1.Number of participants recruited to the CVLP by September 2024 2.Number of participants recruited to the CVLP measured every 12 months until study closure 3.Proportion of eligible patients approached that consent to participate in the CVLP measured every 12 months until study closure 4.Proportion of tumour samples available for analysis measured at 2 weeks post consent to a cancer vaccine trial 5.Number of participants proceeding to participate in a cancer vaccine trial measured monthly until study closure | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of sequencing outputs from NHS laboratories used for manufacturing of therapeutic personalised cancer vaccines measured every 12 months until study closure | — |
Countries
England, United Kingdom
Outcome results
None listed